Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.66 |
| ▸ | MARS1 | P56192 | 6/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 2/20 | 0.41 |
| ▸ | F3 | P13726 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30069186 | 1.00 | NOTUM (0.66) | NOTUMMARS1ALPLSRD5A2DAO | |
| SCHEMBL10900803 | 0.80 | DYRK1A (0.61) | NOTUMMARS1ALPLSRD5A2ALDH1A1 | |
| SCHEMBL16102940 | 0.80 | ALPL (0.49) | NOTUMMARS1ALPLTP53TSHR | |
| SCHEMBL8779218 | 0.80 | SRD5A2 (0.68) | MARS1ALPLSRD5A2ALDH1A1TP53 | |
| SCHEMBL1928413 | 0.80 | NOTUM (1.00) | NOTUMALPLDAOCCNCCDK8 | |
| SCHEMBL2909979 | 0.78 | MMP2 (0.44) | MARS1 | |
| SCHEMBL16115227 | 0.77 | CCNC (0.77) | NOTUMMARS1DAOCCNCCDK8 | |
| SCHEMBL25180562 | 0.75 | NOTUM (0.68) | NOTUMDAOCCNCCDK8 | |
| SCHEMBL20792335 | 0.75 | CNR1 (0.55) | — | |
| SCHEMBL20792337 | 0.75 | CNR1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111148734-B | Pyrrole-2-formamide compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-01-06 | — | — | CN | disclosed |
| CN-111148734-A | Pyrrole-2-formamide compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2020-05-12 | — | — | CN | disclosed |
| WO-2019042267-A1 | PYRROLE-2-FORMAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATIONS THEREOF | 中国医学科学院药物研究所 | 2019-03-07 | — | — | WO | disclosed |
| EP-1537099-B1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-1537099-B1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-08-11 | — | — | EP | disclosed |
| US-7671049-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-7250443-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1537099-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004018455-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | NOTUM 731/4885MARS1 4077/4885ALPL 980/4885 |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | GSK3B, GSK3A, PYGB | NOTUM 731/4885MARS1 4077/4885ALPL 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.